<DOC>
	<DOCNO>NCT01999894</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety tolerability memantine treatment autism pediatric patient .</brief_summary>
	<brief_title>Open-label Study Safety Tolerability Memantine Children With Autism</brief_title>
	<detailed_description>This 48-week multicenter extension study comprise 6-week double-blind dose-titration period follow 42-week open-label maintenance period . In Forest autism trial conduct child age 6-12 , dose extended release formulation memantine weight-based . These weight base dose limit select ensure exposure term area curve ( AUC ) less predefined limit 2100 ng∙h/mL represent 10-fold low exposure observe NOAEL ( No observe adverse effect level ) 15 mg/kg/day juvenile rat . The weight-based dose limit study follow : - Group A : ≥ 60 kg ; max 15 mg/day - Group B : 40-59 kg ; max 9 mg/day - Group C : 20-39 kg ; max 6 mg/day - Group D : &lt; 20 kg ; max 3 mg/day</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Completed leadin study MEMMD57A ( NCT00872898 ) A knowledgeable caregiver capable provide reliable information patient 's condition , able attend clinic visit patient Patients concurrent medical condition might interfere conduct study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Namenda</keyword>
	<keyword>Autism</keyword>
	<keyword>Memantine</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Forest Laboratories</keyword>
</DOC>